Pancreatic Neuroendocrine Cancer

Drug	Drug Name	Drug Description
DB15463	Belzutifan	An inhibitor of hypoxia-inducible factor 2α used as an antineoplastic in the treatment of certain cancers associated with von Hippel-Lindau (VHL) disease.

Drug	Drug Name	Target	Type
DB15463	Belzutifan	Endothelial PAS domain-containing protein 1	target
DB15463	Belzutifan	UDP-glucuronosyltransferase 2B17	enzyme
DB15463	Belzutifan	Cytochrome P450 2C19	enzyme
DB15463	Belzutifan	Cytochrome P450 3A4	enzyme
DB15463	Belzutifan	P-glycoprotein 1	transporter
DB15463	Belzutifan	Solute carrier organic anion transporter family member 1B1	transporter
DB15463	Belzutifan	Solute carrier organic anion transporter family member 1B3	transporter
DB15463	Belzutifan	Multidrug and toxin extrusion protein 2	transporter

Drug	Drug Name	Phase	Status	Count
DB09073	Palbociclib	2	Completed	1